We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04849364
Recruitment Status : Recruiting
First Posted : April 19, 2021
Last Update Posted : January 13, 2023
Sponsor:
Collaborators:
Genentech, Inc.
Pfizer
Foundation Medicine
Indiana University
Epic Sciences
Vera Bradley Foundation for Breast Cancer Research
Information provided by (Responsible Party):
Bryan Schneider, MD, Hoosier Cancer Research Network

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2029
Estimated Study Completion Date : January 31, 2034